$ESALY News
Last published 1y ago
- 1y agoBMYBIIBESALYLLYBristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drugCNBCBristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the latter part of the year.
- 2y agoESALY4523.T-JPBIIBAlzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatmentCNBCLeqembi's rollout has been slowed by bottlenecks related to reimbursement uncertainties, diagnostic test requirements and regular brain scans, among others.
- 2y agoBIIBESALYBiogen tops quarterly profit estimates as cost cuts take hold, Leqembi launch picks upCNBCAlzheimer's drug Leqembi brought in in approximately $19 million in sales for the quarter, up from the $10 million the drug generated last year.
- 2y agoBIIBESALYHealthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow startCNBCThe Alzheimer's drug Leqembi from Biogen and Eisai is seeing a slow launch, but demand is rising. Meanwhile, headsets are making some users nauseous.
- 2y agoBIIBESALYSAGEBiogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapiesCNBCThe results come amid the rollout of Biogen and Eisai's Leqembi, the first drug found to slow the progression of Alzheimer's to win FDA approval.
- 3y agoDGXLLYBIIB4523.T-JP+3Alzheimer’s patients may wait years to get treated with new drugs, putting them at risk of more severe diseaseCNBCPatients could face wait times ranging from 18 months to four years or more to get diagnosed and then treated for Alzheimer's disease.
- 3y agoBIIBESALYAlzheimer's: Medicare will cover Leqembi for all patients if FDA approves drug, CMS chief saysCNBCMedicare has severely restricted access to the medication Leqembi, which costs $26,500 per year, because the FDA approved it just on an expedited basis.
- 3y agoLLYBIIBESALYBiogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO saysCNBCBiogen CEO Christopher Viehbacher said during an earnings call that Eli Lilly needs to consider maintenance doses its Alzheimer's treatment donanemab.
- 3y agoLLYBIIBESALYEli Lilly says experimental Alzheimer's drug reduces brain plaque in early studyCNBCEli Lilly said a higher dose of the up-and-coming Alzheimer's treatment, remternetug, had a larger effect on clearing amyloid plaque.
- 3y agoESALYBIIBVeterans' Health will cover Alzheimer's treatment Leqembi for some patientsCNBCVeterans with early Alzheimer's who meet certain VHA criteria can get the treatment covered, according to Eisai.
- 3y agoESALYBIIBMedicare rejects Alzheimer's Association request for unrestricted coverage of treatments like LeqembiCNBCThe Alzheimer's Association, in a statement Wednesday, said it was "appalled" by CMS' decision.
- 3y agoESALYBIIBSenators call on Medicare to offer broad coverage of Alzheimer's treatments as public pressure growsCNBCEighteen Republicans and two Democrats, led by Sens. Susan Collins and Shelley Moore Capito, pushed Medicare to expand coverage for Alzheimer's treatments.
- 3y agoBIIBESALYTYO:4523EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER'S DISEASE IN JAPANPR NewswireTOKYO and CAMBRIDGE, Mass., Jan. 15, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO:
- 3y agoESALYTYO:4523Eisai's Commitment to Scientific Evidence and Patient SafetyPR NewswireHope for Patients with Early Alzheimer's Disease TOKYO, Jan. 6, 2023 /PRNewswire/ -- LEQEMBI™ (lecanemab-rimb) has the potential to make a difference for people living with early Alzheimer's disease (AD),
- 3y agoBIIBESALYTYO:4523EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINAPR NewswireTOKYO and CAMBRIDGE, Mass., Dec. 22, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO:
- 3y agoALPMYDSNKYESALYTAK+4Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical PackagingPR NewswireTOKYO and OSAKA, Japan, Dec. 21, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, "Astellas"), Eisai Co., Ltd. (TSE: 4523, CEO: Haruo Naito, "Eisai"), Daiichi
- 3y agoBIIBESALYTYO:4523ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE IN THE NEW ENGLAND JOURNAL OF MEDICINEPR NewswireTOKYO and CAMBRIDGE, Mass., Nov. 29, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO:
- 3y agoBIIBESALYTYO:4523EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE AT CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCEPR NewswireTOKYO and CAMBRIDGE, Mass., Nov. 29, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO:
- 4y agoESALYTYO:4523Eisai Announces Key Executive Appointment for Alzheimer's Disease LeadershipPR NewswireThomas D. Fagan Jr. Appointed Vice President, U.S. Alzheimer's Disease Commercial at Eisai Inc. NUTLEY, N.J., July 27, 2022 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of
- 4y agoESALYTYO:4523EISAI TO PRESENT THE LATEST LECANEMAB DATA, INCLUDING ARIA-E AND SUBCUTANEOUS FORMULATION, AND OTHER ALZHEIMER'S DISEASE RESEARCH AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022PR NewswireTOKYO, July 25, 2022 /PRNewswire/ -- Eisai Co. Ltd (Headquarters: Toyoko, CEO: Haruo Naito, "Eisai") announced today that the company will present research from its Alzheimer's disease (AD) pipeline, including new data for lecanemab (BAN2401), an investi
- 4y agoESALYTYO:4523EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT THE 36TH ANNUAL SLEEP 2022 MEETINGPR NewswireNUTLEY, N.J., June 2, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant
- 4y agoBIIBESALYTYO:4523EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAYPR NewswireTOKYO and CAMBRIDGE, Mass., May 9, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, ", Biogen", ))) announced toda
- 4y agoESALYTYO:4523Geisinger, Eisai team up to study use of artificial intelligence for early detection and identification of cognitive impairment that could indicate dementias, including Alzheimer's diseasePR NewswireResearch collaboration will test novel algorithm's effectiveness on Geisinger data DANVILLE, Pa. and NUTLEY, N.J., April 4, 2022 /PRNewswire/ -- Geisinger and Eisai Inc. today announced a collaborative effort to study the potential effectiveness of an
- 4y agoESALYTYO:4523Sysmex Presents Academic Report in Effort to Create a Simple Blood Test to Diagnose Alzheimer's DiseasePR NewswireThe Content Presented at the International Conference on Alzheimer's & Parkinson's Diseases: (AD/PD™ 2022) KOBE, Japan and TOKYO, March 22, 2022 /PRNewswire/ -- Sysmex Corporation (Chairman and CEO: Hisashi Ietsugu; hereafter, "Sysmex") and Eisai C
- 4y agoBIIBESALYTYO:4523LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS - PRESENTED AT AD/PD™ 2022 ANNUAL MEETINGPR NewswireTOKYO and CAMBRIDGE, Mass., March 21, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, ", Biogen", ))) announced t
- 5y agoESALYTYO:4523Eisai Presents New Data on the Relationship between Clinical, Biomarker and Safety Outcomes from the Lecanemab Phase 2b Study for Early Alzheimer's disease in Late-Breakers and Pipeline Updates at the Clinical Trials on Alzheimer's Disease (CTAD) ConferencePR NewswireTOKYO, Nov. 4, 2021 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the presentation of data from the company's extensive Alzheimer's disease (AD) pipeline, including six oral presentations that will provi
- 5y agoESALYTYO:4523Eisai Alzheimer's Disease Pipeline Research, Including New Lecanemab (BAN2401) Data, to be Presented at 2021 Alzheimer's Association International Conference (AAIC)PR NewswireWOODCLIFF LAKE, N.J., July 22, 2021 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of findings from the company's robust Alzheimer's disease (AD) pipeline, including lecanemab (BAN2401)